Social Return on Investment
This is a guest post by Oleksandr Topachevskyi at Digital Health Outcomes. Oleksandr may be contacted at sales@digitalho.com Commercial, nonprofit, […]
This is a guest post by Oleksandr Topachevskyi at Digital Health Outcomes. Oleksandr may be contacted at sales@digitalho.com Commercial, nonprofit, […]
This is a guest post by Ray Miller and Megan E. Bowers, Ph.D. at DLA Piper. Ray may be contacted
The value of method of use patent claims in protecting your therapeutic assets Read Post »
This paper was originally published by Andreas H. Göller, Lara Kuhnke, Floriane Montanari, Anne Bonin, Sebastian Schneckener, Antoniuster Laak, Jörg
This paper was originally published by Md. Imtiaz Hasan et al in Journal of Biosciences and Medicines under a Creative Commons
This article was originally published by Sajna T. in Management Insight, 16(1):38-40 under a creative commons license. Abstract Business enterprises
This is a guest post by Shamil Gizatullin, Gowling WLG (International) Inc. shamil.gizatullin@gowlingwlg.com Although it has become harder to obtain
Getting the most out of pharmaceutical patent-term extensions in Russia Read Post »
By Nanette Moss, S.M., C.I.H., Senior Scientist and Project Executive with Environmental Health & Engineering, Inc. What is business continuity
Business Continuity and Resiliency Planning for Biomedical and Research Organizations Read Post »
This is a guest post from Pepper Hamilton Partners John P. Isacson and N. Nicole Stakleff. John can be contacted
Obviousness-Type Double Patenting Just Became Less of a Problem for Innovators Read Post »
Former Congressman Henry Waxman was recently interviewed for the Clause 8 podcast about how he worked together with Sen. Orrin
Clause 8 Podcast Interview with Co-Author of the Hatch-Waxman Act Read Post »